ScreenerHero

TMO Thermo Fisher Scientific Inc Common Stock

NYSE · US · Healthcare · Diagnostics & Research · thermofisher.com
666.99USD+1.86%Mkt Cap: 242.11B $P/E: 35.53

Thermo Fisher Scientific Inc. provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services internationally. It operates through four segments: Life Scien…

Industry Peers

Diagnostics & Research
Screen all
DHR
Danaher Corporation Common Stock
$150.48BUSDP/E 38.2
NTRA
Natera, Inc. - Common Stock
$59.15BUSD
LONN
Lonza Group AG
$45.82BUSDP/E 38.1
A
Agilent Technologies, Inc. Common Stock
$47.30BUSDP/E 33.1
IQV
IQVIA Holdings, Inc. Common Stock
$42.50BUSDP/E 32.2
WAT
Waters Corporation Common Stock
$41.75BUSDP/E 107.4
ILMN
Illumina, Inc. - Common Stock
$41.23BUSDP/E 50.8
IDXX
IDEXX Laboratories, Inc. - Common Stock
$40.89BUSDP/E 36.4
MTD
Mettler-Toledo International, Inc. Common Stock
$29.78BUSDP/E 34.0
DGX
Quest Diagnostics Incorporated Common Stock
$25.75BUSDP/E 25.0
LH
Labcorp Holdings Inc. Common Stock
$25.02BUSDP/E 25.5
GH
Guardant Health, Inc. - Common Stock
$23.86BUSD
RVTY
Revvity, Inc. Common Stock
$16.91BUSDP/E 72.5
MEDP
Medpace Holdings, Inc. - Common Stock
$16.73BUSDP/E 35.2
ERF
Eurofins Scientific SE
$14.05BUSDP/E 26.2
CRL
Charles River Laboratories International, Inc. Common Stock
$13.85BUSD
ICLR
ICON plc - Ordinary Shares
$12.50BUSDP/E 249.3
BIM
bioMérieux S.A.
$10.02BUSDP/E 20.0
QGEN
Qiagen N.V. Common Shares
$9.24BUSDP/E 22.7
GRAL
GRAIL, Inc. - Common Stock
$6.40BUSD

Key Statistics

Company
Market Cap242.11B USD
Enterprise Value280.72B USD
Revenue (TTM)46.34B USD
Gross Profit18.24B USD
Net Income (TTM)6.70B USD
Revenue/Share123.89 USD
Last Price666.99 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees125.0K
CountryUS
SectorHealthcare
IndustryDiagnostics & Research
ISIN—
Valuation
P/E (Trailing)35.53
P/E (Forward)23.77
PEG1.95
EV/EBITDA23.91
EV/Revenue6.06
P/S5.23
P/B4.60
EPS (TTM)18.58
EPS (Forward)27.55
52W Range
435.2793% of range683.63
52W High683.63 USD
52W Low435.27 USD
Profitability
Gross Margin40.93%
Oper. Margin18.75%
EBITDA Margin25.34%
Profit Margin15.05%
ROE12.55%
ROA6.08%
Growth
Revenue Growth10.50%
Earnings Growth9.40%
Cash Flow & Leverage
Operating CF7.82B USD
CapEx (TTM)1.52B USD
FCF Margin13.46%
FCF Yield2.58%
Net Debt38.48B USD
Net Debt/EBITDA3.28
Balance Sheet
Debt/Equity0.74
Current Ratio1.55
Quick Ratio1.01
Book Value/Sh142.47 USD
Cash/Share10.99 USD
Dividends
Fwd Div Rate1.88 USD
Trail. Div Rate1.80 USD
Div. Yield0.29%
5Y Avg Yield0.25%
Payout Ratio9.69%
Ex-Div DateSep 15, 2026
Pay DateOct 15, 2026
Splits
Last Split3:2
Split DateJun 6, 1996
Analyst Consensus
Rating1.5 (Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)652.85 USD
Upside (mean)-2.1%
Target Range520.00 USD – 780.00 USD
520.00-2.1% to mean780.00
# Analysts26
Ownership
Shares Out.369.75M
Float368.82M
Insiders0.13%
Institutions94.03%
Short Interest
Short Ratio2.9d
Short % Float1.36%
Short % Out.1.36%
Shares Short5.02M
Short (prev mo.)4.74M
Technical
SMA 50617.45 (+8.0%)
SMA 200542.61 (+22.9%)
Beta0.85
S&P 52W Chg14.58%
Avg Vol (30d)1.99M
Avg Vol (10d)2.11M
Technical Indicators
RSI (14)56.8
MACD16.9170
MACD Signal18.6428
MACD Hist.-1.7257
BB Upper701.79 USD
BB Middle646.26 USD
BB Lower590.73 USD
BB Width17.18%
ATR (14)15.40 USD
Vol Ratio (20d)0.74x